{
  "docId": "019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "docSlug": "03e126adc7ca1480",
  "documentTitle": "20250114 bayer handout jpm 2025",
  "authorId": "JPMorgan",
  "authorName": "Bayer",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 12,
  "pageCount": 18,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "initiative_list",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 3,
  "notes": "The slide uses a side-by-side comparison structure to detail two distinct therapeutic programs.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "big_number",
    "callout_box",
    "process_diagram"
  ],
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-9cdc5d048fe2/12",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-9cdc5d048fe2#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.1,
        "y": 0.75
      },
      "kind": "callout",
      "text": "Positive CHMP on Dec 13",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fc2a529-29aa-43c7-939d-b1199243740a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "callout",
      "text": "36% reduction in combined endpoint, showing benefits already after 3 months of treatment and 50% reduction in CV hospitalizations",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-2301-748f-910f-95b34f347fd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.4,
        "x": 0.55,
        "y": 0.6
      },
      "kind": "diagram",
      "text": "OASIS 1, 2, 3, 4 study timeline",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2afa9088-ad95-4000-a88e-b88a0781d9ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.1,
        "y": 0.32
      },
      "kind": "list",
      "text": "Potential New Treatment Option in ATTR-CM; Addressing high medical need; ATTRibute-CM showed highly significant results; In-licensed from BridgeBio",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8407897c-5295-4c1e-97e6-8721d9798272",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.4,
        "x": 0.55,
        "y": 0.32
      },
      "kind": "list",
      "text": "First non-hormonal, oral, dual neurokinin-1,3 receptor antagonist; Up to 80% of women experience VMS; 2 out of 3 women will not be treated with hormones; OASIS 1-4 program showed significant reduction",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e8c89e6-d1cb-4642-bcf2-1585549ff207",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.4,
        "x": 0.1,
        "y": 0.52
      },
      "kind": "metric",
      "text": "36% reduction in combined endpoint",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7a5290f-e6fe-4078-8bc6-0efa45584ada",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "reduction in combined endpoint: 36%",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-2301-748f-910f-99fe7fc6b658",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.78,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Expect first launches in H2 2025",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85f5fe66-795f-4b88-a570-e6d4f2660593",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.33,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Expect first launches in H1 2025",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad49b7e5-ea91-4e09-bbb3-83c5e9665e25",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.08,
        "y": 0.05
      },
      "kind": "title",
      "text": "Leveraging our Market-Leading Positions in CV and WH to Drive Further Growth Momentum",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d4b9b743-fe8d-46d9-acc7-4e47c7b1e0aa",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "f381b448-fcf0-4030-b26e-c9fd2c74d1c9",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The slides showcase the company's market-leading positions and innovation",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 12,
      "from": 4,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6ade2762-544e-41aa-adcf-f0724dca9dce",
      "evidence": "The slides highlight the company's 'why', 'what', and 'how'",
      "position": 1,
      "objective": "Why is Bayer's strategic agenda important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.6,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}